Medicare Plans Releases Survey Results Regarding Medical Cannabis Coverage
April 18th 2022Medicare Plans, a patient support center that provides resources for better understanding Medicare, recently conducted a survey about the idea of Medicare coverage for medical cannabis treatment and products. Here are some highlights from their results.
Senate Majority Leader Chuck Schumer Announces Updates to Bill to Federally Legalize Cannabis
March 10th 2022In February, Senate Majority Leader Chuck Schumer explained in a press conference and in a letter to colleagues the details of his bill to federally legalize cannabis and announced his plan to introduce it in the coming weeks.
NFL Awards $1 Million for Studies on Cannabinoids’ Effects on Pain Management for Athletes
February 23rd 2022The National Football League (NFL) is awarding $1 million in research funding to two teams of medical researchers to study the effects of cannabinoids on pain management and neuroprotection from concussion in elite football players.
MJH Life Sciences™ Announces Acquisition of Cannabis Science Conference
February 21st 2022MJH Life Sciences™ announces the acquisition of the Cannabis Science Conference, which hosts the world's largest and most technical scientific and medical cannabis events and is aimed at improving cannabis science and education.
CannMed 2022: Medical Practicum Organizers Share Their Insight, Part I: Dr. Bonni Goldstein
January 31st 2022The upcoming CannMed conference—taking place May 3–5 in Pasadena, California—will feature an exciting full-day medical practicum organized by Bonni Goldstein, MD, (the practicum’s originator); Dustin Sulak, DO; Kevin Spelman, PhD, MCPP; and Eloise Theisen, NP, AGPCNP-BC. During this practicum, each of the presenters will share the latest research, their clinical experience, and practice guidelines related to cannabinoid therapeutics.
DEA Awards Licenses for Cannabis Production and Medical Research to Royal Emerald Pharmaceuticals
January 19th 2022Royal Emerald Pharmaceuticals, a leading cannabis pharmaceutical company, announced it has received four licenses from the DEA to grow, research, develop, and manufacture alternative drugs derived from cannabis and other botanicals.